April 2017 Vol 8, No 4
We’re gearing up for our first meeting of 2017! The Academy of Oncology Nurse & Patient Navigators (AONN+) is venturing out west to Phoenix, AZ, this month to host our West Coast Regional Meeting.
An Interview with Crystal Dugger, RN, BSN, MBA, of Sarah Cannon, the Cancer Institute of HCA
Medication Adherence Among Patients with Chronic Myeloid Leukemia: The Impact of Financial Burden and Psychosocial Distress
Joanne S. Buzaglo, PhD, Clare Karten, MS, Margaret L. Longacre, PhD, Melissa F. Miller, PhD, MPH, Eberechukwu Onukwugha, MS, PhD, Elisa S. Weiss, PhD
The authors present their findings on a study addressing interventions that foster patient-clinician communication and referral for services related to both financial need and psychosocial distress to ensure optimal adherence to CML therapy.
Recently, a member from the Smart Patients ovarian cancer community asked, “What do you wish you knew when you were first diagnosed?” The responses ran the emotional, social, and practical gamut. We share their comments in an effort to help navigators understand the needs of newly diagnosed patients.
A beautiful case study exemplifying the power of navigation when executed in collaboration with the patient, caregivers, and care team.
Active surveillance is gaining ground as a strategy for managing small renal masses. According to intermediate follow-up of the prospective Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry, active surveillance appears as safe as primary intervention in selected patients. In general, active surveillance is a good option for elderly patients with comorbidities and renal masses <4 cm.
Atezolizumab plus bevacizumab showed encouraging responses as a first-line approach to treatment of metastatic renal cell carcinoma (mRCC) in a phase 2 trial.
Despite consultations with oncologists about the goal of treatment, more than one-third of men with incurable prostate cancer believed that a cure was possible with the treatments they were about to receive.
Reduced-Dose Sorafenib with Uptitration in Hepatocellular Carcinoma Is Cost-Saving Without Compromising Outcome
Starting at a low dose of sorafenib and titrating up to the full dose of 800 mg, rather than starting at the full dose, does not adversely affect outcomes and improves tolerability and reduces costs in the treatment of patients with hepatocellular carcinoma (HCC).
Adding vemurafenib to cetuximab and irinotecan prolonged progression-free survival (PFS) and improved the disease control rate in patients with BRAF V600E mutation–positive colorectal cancer (CRC).
Page 1 of 2
Results 1 - 10 of 14
Results 1 - 10 of 14